What is Arocell?
Saving lives with diagnostics.
– We provide knowledge to decision.
– AroCell Group consist of AroCell AB and IDL Biotech.
Meet us at WHX Labs Dubai 10-13 February
We will be co-exhibiting together with our partner concile at Booth SA.A55. Come by our booth and learn more about our products and how quantitative point-of-care testing can be used to provide accurate and rapid results.
IDL Diagnostics participates at RedEye Theme Event Fight Cancer
On January 21st Redeye hosted a Fight Cancer 2026 theme event where CEO Anders Hultman presented about the company, market opportunities and the new strategic priority. See the presentation here
Strategy update: IDL Diagnostics
A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...
UBC® Rapid | Bladder Cancer detection
A powerful Doctors-office test (Point-of-Care), for aid in the diagnosis and monitoring of bladder cancer. Read more about UBC® Rapid
TUBEX® TF | Rapid Typhoid Detection
A rapid and sensitive in vitro diagnostic test for detection of acute typhoid fever, a disease caused by Salmonella typhi. Read more about TUBEX® TF
TK 210 ELISA | Cell Proliferation Biomarker
The AroCell TK 210 ELISA kit used for therapy response in subjects with many forms of cancer including several solid tumors. Read more about TK 210 ELISA
Tumor markers licensed to strategic partners
Arocell is constantly building partnerships for establishing projects and developing new products to expand its portfolio. Read More about tumor markers
Press Releases
About us
We provide knowledge to decision.
IDL Diagnosticsis a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of diseases.
Investors
We are listed on NASDAQ First North Growth Market.
We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. IDL Diagnostics is unique for a company of this size.
